Stockscreener 앱 받기
9.23
3.02%
0.30
시간 외 거래:
9.22
-0.010
-0.11%
전일 마감가:
$8.93
열려 있는:
$9.16
하루 거래량:
959.37K
Relative Volume:
0.84
시가총액:
$977.36M
수익:
$247.00M
순이익/손실:
$-249.00M
주가수익비율:
-2.9871
EPS:
-3.09
순현금흐름:
$-267.00M
1주 성능:
+2.00%
1개월 성능:
+0.88%
6개월 성능:
-42.28%
1년 성능:
-38.95%
1일 변동 폭
$8.76
$9.40
1주일 범위
$8.55
$9.61
52주 변동 폭
$6.50
$18.98
Arcus Biosciences Inc Stock (RCUS) Company Profile
명칭
Arcus Biosciences Inc
전화
(510) 694-6200
주소
3928 POINT EDEN WAY, HAYWARD, CA
RCUS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
9.23 | 956.14M | 247.00M | -249.00M | -267.00M | -3.09 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-26 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-10-21 | 개시 | H.C. Wainwright | Neutral |
| 2024-10-08 | 개시 | Wells Fargo | Overweight |
| 2022-11-18 | 개시 | BofA Securities | Neutral |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2020-11-24 | 개시 | Berenberg | Buy |
| 2020-11-23 | 개시 | Evercore ISI | Outperform |
| 2020-04-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-09-27 | 개시 | Mizuho | Buy |
| 2019-05-24 | 재개 | Citigroup | Buy |
| 2018-10-09 | 개시 | Wedbush | Outperform |
| 2018-04-09 | 개시 | Citigroup | Buy |
| 2018-04-09 | 개시 | Goldman | Neutral |
| 2018-04-09 | 개시 | Leerink Partners | Outperform |
모두보기
Arcus Biosciences Inc 주식(RCUS)의 최신 뉴스
Transcript : Arcus Biosciences, Inc.Special Call - marketscreener.com
Arcus Biosciences Presents Promising Phase 1/1b Trial Data - TipRanks
Two Sigma Investments LP Purchases 11,027 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences (RCUS) Unveils Promising Data for Cancer Treatment | RCUS Stock News - GuruFocus
Arcus Says Initial Data From The Arc-20 Study Of Casdatifan Plus Cabozantinib Showed Nearly Half Of Patients With Metastatic Kidney Cancer Had A Confirmed Response - marketscreener.com
ProShare Advisors LLC Increases Stake in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences (NYSE:RCUS) Shares Down 8.6% – Here’s What Happened - Defense World
Arcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Arcus Biosciences’ SWOT analysis: stock’s potential in cancer therapy market By Investing.com - Investing.com Nigeria
BNP Paribas Financial Markets Purchases 9,016 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Deutsche Bank AG Boosts Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Arcus Biosciences’ SWOT analysis: stock’s potential in cancer therapy market - Investing.com
Arcus Biosciences Announces New Employment Inducement Grants | R - GuruFocus
Arcus Biosciences Announces New Employment Inducement Grants | RCUS Stock News - GuruFocus
Arcus Biosciences Announces New Employment Inducement Grants - Business Wire
Lazard Asset Management LLC Has $93,000 Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Barclays Reaffirms Their Buy Rating on Arcus Biosciences (RCUS) - The Globe and Mail
Recent Investment Analysts’ Ratings Changes for Arcus Biosciences (RCUS) - Defense World
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Bought by Northern Trust Corp - Defense World
Arcus Biosciences Stock May Be The Next To Fail (NYSE:RCUS) - Seeking Alpha
Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Just Slashed This Year's Revenue Estimates By 17% - simplywall.st
Trading (RCUS) With Integrated Risk Controls - news.stocktradersdaily.com
Price T Rowe Associates Inc. MD Sells 6,265 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Morgan Stanley Cuts Arcus Biosciences (NYSE:RCUS) Price Target to $22.00 - Defense World
First Trust Advisors LP Has $264,000 Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Cantor Fitzgerald Has Weak Forecast for RCUS FY2025 Earnings - Defense World
HC Wainwright Predicts Weaker Earnings for Arcus Biosciences - Defense World
Arcus Biosciences (RCUS): Morgan Stanley Lowers Price Target | R - GuruFocus
Wedbush Decreases Earnings Estimates for Arcus Biosciences - Defense World
Raymond James Financial Inc. Makes New Investment in Arcus Biosciences, Inc. (NYSE:RCUS) - Defense World
Morgan Stanley Lowers Price Target on Arcus Biosciences to $22 From $24, Keeps Overweight Rating - marketscreener.com
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates - MSN
Goldman Sachs Adjusts Price Target for Arcus Biosciences (RCUS) - GuruFocus
Goldman Sachs Adjusts Price Target for Arcus Biosciences (RCUS) | RCUS Stock News - GuruFocus
Wells Fargo Adjusts Price Target for Arcus Biosciences (RCUS) to $26 | RCUS Stock News - GuruFocus
Arcus Biosciences First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Arcus Biosciences (RCUS) Receives Adjusted Price Target from Wel - GuruFocus
Arcus Biosciences (NYSE:RCUS) Shares Gap Down on Disappointing Earnings - Defense World
Analyzing Ratios: Arcus Biosciences Inc (RCUS)’s Financial Story Unveiled - DWinneX
European regulators to review Valneva shot; Jazz's stock dips on subpar first-quarter revenue - Endpoints News
Arcus Biosciences, Inc. (NYSE:RCUS) Q1 2025 Earnings Call Transcript - MSN
Arcus Biosciences (RCUS) Receives Adjusted Price Target from Wells Fargo | RCUS Stock News - GuruFocus
Arcus Biosciences, Inc. (NYSE:RCUS) Shares Purchased by Dimensional Fund Advisors LP - Defense World
Arcus Biosciences Q1 2025 Earnings Call Transcript - MarketBeat
Arcus Biosciences Inc (RCUS) Q1 2025 Earnings Call Highlights: Strategic Focus and Financial ... - Yahoo Finance
Arcus Biosciences Inc (RCUS) Q1 2025 Earnings Call Highlights: Strategic Focus and Financial ... By GuruFocus - Investing.com Canada
Arcus Biosciences earnings missed by $0.12, revenue fell short of estimates - Investing.com Canada
Earnings call transcript: Arcus Biosciences Q1 2025 misses earnings estimates - Investing.com
Earnings call transcript: Arcus Biosciences Q1 2025 misses earnings estimates By Investing.com - Investing.com India
Arcus Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Arcus Biosciences (RCUS) Misses Q1 Revenue Expectations, Outlines Future Plans | RCUS Stock News - GuruFocus
Arcus Biosciences Inc (RCUS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
6.29%
자본화:
|
볼륨(24시간):